The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.

Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression ... report on Spravato (esketamine) and says the drug would need to be between 25% and 52% cheaper ...

But you should take doses of the nasal corticosteroid or nasal decongestant at least 1 hour before you receive a dose of Spravato. In studies of Spravato, the nasal decongestant oxymetazoline was ...

Tesla and SpaceX CEO Elon Musk clarified that he uses only "a small amount once every other week or something like that" ...

The Food and Drug Administration (FDA) recently expanded approval for Spravato, an antidepressant nasal spray used to treat depression. Parkside Psychiatric Hospital has a Spravato outpatient ...

This is because the Food and Drug Administration (FDA ... S-ketamine, or esketamine (Spravato), is an FDA-approved nasal spray that doctors and healthcare professionals may prescribe for major ...

The UK agency declined to recommend NHS funding for Spravato (esketamine) nasal spray in 2020 – following ... convinced by the clinical data for the drug and believed it was not cost-effective.

Medicare doesn’t currently cover ketamine infusions for mental health conditions, as the Food and Drug Administration ... also called esketamine (Spravato), is a nasal spray with FDA approval ...